332 related articles for article (PubMed ID: 8215747)
1. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy.
Hollenberg NK; Raij L
Arch Intern Med; 1993 Nov; 153(21):2426-35. PubMed ID: 8215747
[TBL] [Abstract][Full Text] [Related]
2. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
3. Ace inhibition in renal disease: risks and benefits.
Campanacci L; Fabris B; Fischetti F; Bardelli M; Vran F; Carretta R
Clin Exp Hypertens; 1993; 15 Suppl 1():173-86. PubMed ID: 8513308
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin converting enzyme inhibitors and progression of chronic renal failure.
Tolins JP; Raij L
Kidney Int Suppl; 1990 Nov; 30():S118-22. PubMed ID: 2259070
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
6. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition in renal disease; contrasting effects on renal function in renal artery stenosis and progressive renal injury.
Jackson B; Johnston CI
J Hum Hypertens; 1989 Jun; 3 Suppl 1():107-15. PubMed ID: 2674436
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
Elliott HL
Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
Crook ED; Preddie DC
Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
[TBL] [Abstract][Full Text] [Related]
10. [ACE inhibitors' effect on kidney function].
Grönhagen-Riska C
Nord Med; 1990; 105(8-9):219-22. PubMed ID: 2216687
[TBL] [Abstract][Full Text] [Related]
11. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of converting-enzyme inhibitors in renal disease.
Anderson S; Brenner BM
Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):81-7. PubMed ID: 3037894
[TBL] [Abstract][Full Text] [Related]
13. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
Barnas U; Mayer G
Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
[TBL] [Abstract][Full Text] [Related]
14. Hypertension with co-existing renal disease.
Bauer JH; Reams GP
J Hum Hypertens; 1990 Dec; 4 Suppl 5():27-34. PubMed ID: 2090835
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease.
Raij L
Am J Hypertens; 2005 Apr; 18(4 Pt 2):95S-99S. PubMed ID: 15837551
[TBL] [Abstract][Full Text] [Related]
17. Methods of cardio-renal protection in non-diabetic chronic nephropathies.
Ruggenenti P; Remuzzi G
Rocz Akad Med Bialymst; 2004; 49():116-23. PubMed ID: 15631326
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
Cantarovich F; Rangoonwala B
Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
[TBL] [Abstract][Full Text] [Related]
19. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of hypertension in renal parenchymal diseases].
Iversen BM; Kvam FI; Svarstad E
Tidsskr Nor Laegeforen; 1996 Jun; 116(17):2022-6. PubMed ID: 8766645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
